Puma Biotechnology is Pharmaceuticals in United States that focus on potential commercialization business. Founded in 2007. They cover business area such as Puma Biotechnology, novel therapeutic, cancer, its current drug candidate, its product pipeline, license, research, development, potential commercialization, potential drug candidate, discipline decision criterion, at least some clinical study.
2007
( 17 years old in 2024 )
Potential Commercialization
-
10880 Wilshire Boulevard
Suite 2150
Los Angeles, CA 90024
United States
Private
Puma Biotechnologynovel therapeuticcancerits current drug candidateits product pipelinelicenseresearchdevelopmentpotential commercializationpotential drug candidatediscipline decision criterionat least some clinical study
* We use standard office opening hours in near Puma Biotechnology's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Puma Biotechnology is Pharmaceuticals business from United States that founded in 2007 (17 years old in 2024), Puma Biotechnology business is focusing on Potential Commercialization.
Puma Biotechnology headquarter office and corporate office address is located in 10880 Wilshire Boulevard Suite 2150 Los Angeles, CA 90024 United States.
Puma Biotechnology was founded in United States.
In 2024, Puma Biotechnology is currently focus on potential commercialization sector.
Above is snippet of Google Trends for "potential commercialization" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Puma Biotechnology, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
